The introduction of S.4031, the Innovative Therapies Centers of Excellence Act, moves psychedelic research into a federal healthcare framework.
The bill, introduced by Sens. Ruben Gallego and David McCormick, would establish specialized research and treatment centers within the Department of Veterans Affairs to study therapies for PTSD, traumatic brain injury, depression, substance use disorders, and chronic pain. The bill specifically names MDMA, psilocybin, ibogaine, ketamine, and 5-MeO-DMT as the compounds under study.
It authorizes funding and requires internal data systems.
From Parallel Efforts to a System
Psychedelic research in the United States has developed in separate tracks. Academic trials, nonprofit funding, and private investment have all advanced with different protocols, small sample sizes, and limited coordination.
S.4031 would bring that work under one federal roof — standardized protocols, formal clinician training, centralized data collection, and multi-site trials.
If passed, it would be one of the most serious federal attempts to run coordinated psychedelic research inside a healthcare institution it already operates.
Why the VA
The VA is not just large. It functions as a single, integrated system.
It tracks patients over long periods, applies consistent standards across sites, and serves a population with high rates of treatment-resistant conditions — making it one of the few places where outcomes can be measured in a way that regulators and insurers will take seriously.
Sen. Gallego was direct about the obligation:
“Too many veterans are suffering without effective treatment options. If emerging therapies like psychedelics show promise, we have a responsibility to study them and ensure veterans have access to the best possible care.”
Melissa Lavasani, founder and CEO of the Psychedelic Medicine Coalition, said in a statement:
“The VA is the right proving ground because the need is already concentrated there. Veterans experience some of the highest rates of PTSD, depression, and suicide in the country, and the VA is the largest integrated healthcare system we have. That combination makes it uniquely positioned to rigorously study and responsibly deliver new treatments.”
Amy Rising, a veteran advocate, framed the underlying obligation:
“Veterans should never feel like the country they served has run out of options for their healing. We owe it to them to pursue every responsible, evidence-based pathway that could improve treatment for PTSD, depression, and other serious health conditions. This legislation helps ensure that promising new therapies are studied rigorously so that veterans and their doctors have better options in the future.”
If these therapies are going to meet federal standards, it will happen here.
What the Bill Does — and Doesn’t Do
S.4031 does not authorize patient access or resolve regulatory barriers. Psychedelics remain outside standard care.
What it does is give the VA the authority to run structured programs capable of answering whether these treatments work at scale.
“What the Centers of Excellence bill does is give the VA the authority and infrastructure to do this the right way,” Lavasani said.
The problem has never been lack of interest or early evidence. It is the absence of large, consistent datasets from real patients in clinical settings. This bill is designed to produce them.
“Passage unlocks the ability to move from small, scattered studies to a coordinated federal effort focused on evidence, safety, and real-world outcomes for veterans. In other words, it creates a credible pathway for determining whether psychedelic-assisted treatments should become part of mainstream care,” she added.
Legitimacy Before Access
Passage would not expand access in the short term. It would generate the kind of evidence federal regulators require before changing standards of care — standardized protocols, reproducible results, long-term outcome data — produced inside an institution that already delivers care at scale.
The field has spent a decade pushing for faster access; this bill reflects a different reality, that without system-level evidence, access does not scale.
Psychedelics Today has consistently argued for access across multiple channels, from clinical settings to decriminalized and traditional use. Federal pathways operate differently. Within that constraint, this bill reflects a credible approach: build the evidence base here, while broader access continues to evolve elsewhere.
Bipartisan, and Targeted
The Senate bill follows the House companion measure, H.R. 2623, introduced by Reps. Lou Correa and Jack Bergman, co-chairs of the Psychedelics Advancing Therapies (PATH) Caucus.
Veterans’ care provides a narrow path forward. It keeps the focus on clinical outcomes and avoids the broader cultural debates that tend to stall policy.
What It Leaves Open
The bill does not address drug scheduling or DEA oversight, workforce development outside federal institutions, reimbursement models, or access beyond the VA. Authorization allows the infrastructure to be built. Funding and implementation determine whether it functions.
What Comes Next
S.4031 was referred to the Senate Committee on Veterans’ Affairs on March 9, 2026. No hearing or markup has been scheduled. Its path forward depends on the committee moving it alongside H.R. 2623 in the House.
Where This Leaves the Field
S.4031 is a decision to build a federal testing ground — a move from observing the field to running studies inside an institution the government already operates.
The question is no longer whether these therapies show promise.
It is whether they hold up under the scrutiny federal adoption requires.
